Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

MT NewswiresApr 2 20:31

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillami...

Stockhouse Mar 27 21:08

Revive Therapeutics to Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID

MT NewswiresMar 19 20:26

Revive Therapeutics To Submit Type C Meeting Request With FDA for Bucillamine to Treat Long COVID

Stockhouse Mar 19 19:00

Revive Therapeutics Provides Corporate Update

MT NewswiresMar 12 20:01

Press Release: Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

Dow JonesFeb 27 05:05